Alkermes (ALKS) Other financing activities (2010 - 2026)
Alkermes (ALKS) posted quarterly Other financing activities of $26.3 million for Q2 2026, up 1162.22% year-over-year from $2.1 million in Q2 2025, and up 67.32% quarter-over-quarter from $15.7 million in Q1 2026.
Alkermes (ALKS) Other financing activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other financing activities for 17 consecutive years, with $26.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other financing activities rose 1162.22% year-over-year to $26.3 million; the TTM figure through Jun 2026 stood at $53.8 million (up 18.65% YoY), while the FY2025 annual figure was $43.4 million, up 57.45% from the prior year.
- Other financing activities improved to $26.3 million in Q2 2026 per ALKS's latest filing, from $15.7 million in the prior quarter.
- Across five years, Other financing activities topped out at $29.5 million in Q1 2025 and bottomed at $622000.0 in Q3 2025.
- Historically, Other financing activities has averaged $8.3 million across 5 years, with a median of $4.3 million in 2023.
- Annual changes were most pronounced in 2025 — Other financing activities tumbled 88.73% — and 2026, when it jumped 1162.22%.
- Alkermes' Other financing activities stood at $780000.0 in 2022, then jumped by 111.15% to $1.6 million in 2023, then soared by 398.97% to $8.2 million in 2024, then jumped by 36.02% to $11.2 million in 2025, then soared by 135.21% to $26.3 million in 2026.
- Business Quant data shows ALKS's Other financing activities at $26.3 million in Q2 2026, $15.7 million in Q1 2026, and $11.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.29 Mn |
| Jun 30, 2026 | 26.29 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | 11.18 Mn |
| Dec 31, 2025 | 11.18 Mn |
| Sep 30, 2025 | 622,000.00 |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Mar 31, 2024 | 11.23 Mn |